. As of December31, 2025, we had an accumulated deficit of $561.7 million. We currently rely and expect to continue to rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND and AQVESME and any product candidate for which we may obtain marketing approval. Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development, marketing approval or our commerci...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001439222-26-000025 | EDGAR | 87K words |
| 2025-02-13 | 2024-12-31 | 0001439222-25-000009 | EDGAR | — |
| 2024-02-15 | 2023-12-31 | 0001439222-24-000035 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001439222-23-000039 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001439222-22-000024 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001439222-21-000029 | EDGAR | — |
| 2020-02-19 | 2019-12-31 | 0001439222-20-000014 | EDGAR | — |
| 2019-02-14 | 2018-12-31 | 0001439222-19-000004 | EDGAR | — |
| 2018-02-14 | 2017-12-31 | 0001439222-18-000004 | EDGAR | — |
| 2017-02-16 | 2016-12-31 | 0001193125-17-046795 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001439222-26-000118 | EDGAR | — |
| 2025-10-30 | 2025-09-30 | 0001439222-25-000116 | EDGAR | 44K words |
| 2025-07-31 | 2025-06-30 | 0001439222-25-000089 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001439222-25-000036 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001439222-24-000138 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001439222-24-000121 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0001439222-24-000069 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0001439222-23-000140 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001439222-23-000119 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001439222-23-000065 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001439222-22-000099 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001439222-22-000070 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-30 | 0001439222-26-000115 | EDGAR | — |
| 2026-02-12 | 0001439222-26-000023 | EDGAR | 2K words |
| 2026-01-12 | 0001439222-26-000018 | EDGAR | — |
| 2025-10-30 | 0001439222-25-000114 | EDGAR | — |
| 2025-08-04 | 0001439222-25-000090 | EDGAR | — |
| 2025-07-31 | 0001439222-25-000087 | EDGAR | — |
| 2025-07-08 | 0001439222-25-000076 | EDGAR | — |
| 2025-06-18 | 0001193125-25-142745 | EDGAR | — |
| 2025-05-01 | 0001439222-25-000034 | EDGAR | — |
| 2025-02-13 | 0001439222-25-000007 | EDGAR | — |
220 total filings indexed. 188 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001439222 |
| Ticker | AGIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.agios.com |
| Listed | 2013-07-24 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AGIO (~200 tokens, structured JSON with cryptographic provenance)